Company press releases

Displaying 101 - 117 of 117 results
Released Company Title Industry Topic
12 Jan 2022
17:45 CET 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S2 2021 20103010 Biotechnology -
14 Dec 2021
17:45 CET 		NFL BIOSCIENCES S.A. NFL Biosciences: Phase II/III clinical trial launched for smoking cessation 20103010 Biotechnology -
14 Dec 2021
17:45 CET 		NFL BIOSCIENCES S.A. NFL Biosciences : lancement de l’étude clinique de Phase II/III pour le sevrage tabagique 20103010 Biotechnology -
17 Nov 2021
17:45 CET 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES: agreement signed with Diverchim to manufacture its active ingredients 20103010 Biotechnology -
17 Nov 2021
17:45 CET 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES : accord de production de ses principes actifs avec Diverchim 20103010 Biotechnology -
04 Oct 2021
08:15 CEST 		NFL BIOSCIENCES S.A. NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021 20103010 Biotechnology -
04 Oct 2021
08:15 CEST 		NFL BIOSCIENCES S.A. NFL Biosciences : Mise à disposition du Rapport Financier Semestriel au 30 juin 2021 20103010 Biotechnology -
04 Oct 2021
08:00 CEST 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES : Activités et résultats du 1er semestre 2021 20103010 Biotechnology -
04 Oct 2021
08:00 CEST 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES: 2021 half-year financial and business report 20103010 Biotechnology -
21 Sep 2021
18:15 CEST 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES : Accord de délivrance de son brevet aux États-Unis 20103010 Biotechnology -
21 Sep 2021
18:15 CEST 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES: approval for its patent to be granted in the United States 20103010 Biotechnology -
15 Sep 2021
18:00 CEST 		NFL BIOSCIENCES S.A. NFL Biosciences : l’étude clinique de Phase II/III de NFL-101 pour le sevrage tabagique approuvée en France 20103010 Biotechnology -
15 Sep 2021
18:00 CEST 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES: Phase II/III clinical trial for NFL-101 for smoking cessation approved in Franc 20103010 Biotechnology -
06 Sep 2021
08:45 CEST 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES: ANALYST COVERAGE LAUNCHED WITH INVEST SECURITIES 20103010 Biotechnology -
06 Sep 2021
08:45 CEST 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES : INITIATION DE COUVERTURE ANALYSTE PAR INVEST SECURITIES 20103010 Biotechnology -
20 Jul 2021
08:00 CEST 		NFL BIOSCIENCES S.A. NFL BIOSCIENCES : MISE EN PLACE D’UN CONTRAT DE LIQUIDITE 20103010 Biotechnology -
05 Jul 2021
08:00 CEST 		NFL BIOSCIENCES S.A. Nfl Biosciences Raises €5.0m Following Its Successful Initial Public Offering on Euronext Growth Paris® 20103010 Biotechnology -